Marinus Pharmaceuticals, Inc. – NASDAQ:MRNS
Marinus Pharmaceuticals stock price today
$0.55
+0.17
+48.02%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 4 hours
Marinus Pharmaceuticals stock price monthly change
-72.92%
month
Marinus Pharmaceuticals stock price quarterly change
-72.92%
quarter
Marinus Pharmaceuticals stock price yearly change
-96.62%
year
Marinus Pharmaceuticals key metrics
Market Cap | 12.57M |
Enterprise value | 179.03M |
P/E | -14.62 |
EV/Sales | 7.02 |
EV/EBITDA | -33.54 |
Price/Sales | 12.39 |
Price/Book | 2.72 |
PEG ratio | -0.18 |
EPS | -2.63 |
Revenue | 28.28M |
EBITDA | -131.78M |
Income | -145.34M |
Revenue Q/Q | -26.02% |
Revenue Y/Y | 30.52% |
Profit margin | -77.78% |
Oper. margin | -442.69% |
Gross margin | 87.05% |
EBIT margin | -442.69% |
EBITDA margin | -465.87% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMarinus Pharmaceuticals stock price history
Marinus Pharmaceuticals stock forecast
Marinus Pharmaceuticals financial statements
| Jun 2023 | 6.08M | -31.93M | -525.14% |
|---|---|---|---|
| Sep 2023 | 7.33M | -32.97M | -449.33% |
| Dec 2023 | 7.19M | -41.76M | -580.93% |
| Mar 2024 | 7.67M | -38.66M | -503.57% |
| Mar 2024 | 7.67M | -38.66M | -503.57% |
|---|---|---|---|
| Sep 2025 | 13.54M | -15.30M | -112.97% |
| Oct 2025 | 14.46M | -11.74M | -81.22% |
| Dec 2025 | 20.54M | -8.52M | -41.51% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 201200000 | 143.86M | 71.5% |
|---|---|---|---|
| Sep 2023 | 200806000 | 146.26M | 72.84% |
| Dec 2023 | 170908000 | 154.14M | 90.19% |
| Mar 2024 | 137350000 | 153.78M | 111.97% |
| Jun 2023 | -24.35M | 5.00M | 237K |
|---|---|---|---|
| Sep 2023 | -25.17M | 11.92M | 25.90M |
| Dec 2023 | -26.99M | 6.46M | 661K |
| Mar 2024 | -37.46M | 20.88M | 257K |
Marinus Pharmaceuticals alternative data
| Aug 2023 | 151 |
|---|---|
| Sep 2023 | 151 |
| Oct 2023 | 151 |
| Nov 2023 | 151 |
| Dec 2023 | 151 |
| Jan 2024 | 151 |
| Feb 2024 | 151 |
| Mar 2024 | 165 |
| Apr 2024 | 165 |
| May 2024 | 165 |
| Jun 2024 | 165 |
| Jul 2024 | 165 |
Marinus Pharmaceuticals other data
81.68%
+0.23%
of MRNS is owned by hedge funds
29.94M
+18.77K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2023 | 0 | 16725 |
| Feb 2024 | 0 | 21803 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | BRAUNSTEIN SCOTT director, officer.. | Common Stock | 50,000 | $4.28 | $214,000 | ||
Option | BRAUNSTEIN SCOTT director, officer.. | Stock Option (Right to Buy) | 50,000 | $4.28 | $214,000 | ||
Sale | SHAFER CHRISTINA officer: CHIEF COMMERCIAL OFFICER | Common Stock | 2,153 | $9.56 | $20,583 | ||
Sale | MANNING MARTHA E officer: SVP, GEN. COUNSEL & CO.. | Common Stock | 1,894 | $9.57 | $18,126 | ||
Sale | HULIHAN JOSEPH officer: CHIEF ME.. | Common Stock | 2,814 | $9.98 | $28,084 | ||
Sale | PFANSTIEL STEVEN officer: CFO AND COO | Common Stock | 3,092 | $9.97 | $30,827 | ||
Sale | BRAUNSTEIN SCOTT director, officer.. | Common Stock | 11,850 | $9.94 | $117,789 | ||
Sale | SHAFER CHRISTINA officer: CHIEF COMMERCIAL OFFICER | Common Stock | 11 | $8.93 | $98 | ||
Sale | BRAUNSTEIN SCOTT director, officer.. | Common Stock | 30 | $8.94 | $268 | ||
Sale | PFANSTIEL STEVEN officer: CFO AND COO | Common Stock | 14 | $8.93 | $125 |
| Patent |
|---|
Application Filling date: 26 Apr 2022 Issue date: 25 Aug 2022 |
Application Filling date: 24 Mar 2022 Issue date: 11 Aug 2022 |
Application Filling date: 1 Mar 2022 Issue date: 7 Jul 2022 |
Grant Filling date: 6 Dec 2019 Issue date: 8 Mar 2022 |
Grant Filling date: 26 Feb 2021 Issue date: 7 Sep 2021 |
Grant Filling date: 2 Oct 2018 Issue date: 27 Jul 2021 |
Application Filling date: 26 Feb 2021 Issue date: 24 Jun 2021 |
Grant Filling date: 25 Mar 2020 Issue date: 11 May 2021 |
Application Filling date: 13 Aug 2020 Issue date: 6 May 2021 |
Grant Filling date: 14 Oct 2016 Issue date: 22 Sep 2020 |
| Quarter | Transcript |
|---|---|
| Q4 2023 5 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 11 May 2023 | Q1 2023 Earnings Call Transcript |
-
What's the price of Marinus Pharmaceuticals stock today?
One share of Marinus Pharmaceuticals stock can currently be purchased for approximately $0.55.
-
When is Marinus Pharmaceuticals's next earnings date?
Unfortunately, Marinus Pharmaceuticals's (MRNS) next earnings date is currently unknown.
-
Does Marinus Pharmaceuticals pay dividends?
No, Marinus Pharmaceuticals does not pay dividends.
-
How much money does Marinus Pharmaceuticals make?
Marinus Pharmaceuticals has a market capitalization of 12.57M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 21.63% to 30.99M US dollars.
-
What is Marinus Pharmaceuticals's stock symbol?
Marinus Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "MRNS".
-
What is Marinus Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Marinus Pharmaceuticals?
Shares of Marinus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Marinus Pharmaceuticals's key executives?
Marinus Pharmaceuticals's management team includes the following people:
- Dr. Scott N. Braunstein M.D. Chief Executive Officer, Pres & Director(age: 62, pay: $898,880)
- Dr. Joseph Hulihan M.D. Chief Medical Officer(age: 69, pay: $488,870)
-
How many employees does Marinus Pharmaceuticals have?
As Jul 2024, Marinus Pharmaceuticals employs 165 workers.
-
When Marinus Pharmaceuticals went public?
Marinus Pharmaceuticals, Inc. is publicly traded company for more then 11 years since IPO on 31 Jul 2014.
-
What is Marinus Pharmaceuticals's official website?
The official website for Marinus Pharmaceuticals is marinuspharma.com.
-
Where are Marinus Pharmaceuticals's headquarters?
Marinus Pharmaceuticals is headquartered at 5 Radnor Corporate Center, Radnor, PA.
-
How can i contact Marinus Pharmaceuticals?
Marinus Pharmaceuticals's mailing address is 5 Radnor Corporate Center, Radnor, PA and company can be reached via phone at +48 48014670.
Marinus Pharmaceuticals company profile:
Marinus Pharmaceuticals, Inc.
marinuspharma.comExchange:
NASDAQ
Full time employees:
165
Industry:
Biotechnology
Sector:
Healthcare
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
5 Radnor Corporate Center
Radnor, PA 19087
Radnor, PA 19087
CIK: 0001267813
ISIN: US56854Q2003
CUSIP: 56854Q200
